Skip directly to page options Skip directly to A-Z link
Volume 27, Number 6—June 2021
Research

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201

Kirsten E. Wiens, Pinyi Nyimol Mawien, John Rumunu, Damien Slater, Forrest K. Jones, Serina Moheed, Andrea Caflisch, Bior K. Bior, Iboyi Amanya Jacob, Richard Lino Lako, Argata Guracha Guyo, Olushayo Oluseun Olu, Sylvester Maleghemi, Andrew Baguma, Juma John Hassen, Sheila K. Baya, Lul Deng, Justin Lessler, Maya N. Demby, Vanessa Sanchez, Rachel Mills, Clare Fraser, Richelle C. Charles2, Jason B. Harris2, Andrew S. Azman3Comments to Author , and Joseph F. Wamala3
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (K.E. Wiens, F.K. Jones, J. Lessler, M.N. Demby, A.S. Azman); Republic of South Sudan Ministry of Health, Juba, South Sudan (P.N. Mawien, J. Rumunu, B.K. Bior, I.A. Jacob, R.L. Lako, L. Deng); Massachusetts General Hospital, Boston, Massachusetts, USA (D. Slater, S. Moheed, V. Sanchez, R. Mills, C. Fraser, R.C. Charles, J.B. Harris); International Organization for Migration, Juba (A. Caflisch); World Health Organization, Juba (A.G. Guyo, O.O. Olu, S. Maleghemi, A. Baguma, J.J. Hassen, S.K. Baya, J.F. Wamala); Kabale University School of Medicine, Kabale, Uganda (A. Baguma); Harvard Medical School, Boston (R.C. Charles, J.B. Harris); Médecins Sans Frontières, Geneva, Switzerland (A.S. Azman); Institute of Global Health, Geneva (A.S. Azman)

Main Article

Figure 1

Number of weekly SARS-CoV-2 tests and infections reported in Juba, South Sudan, May 3–October 30, 2020. The survey of seroprevalence of SARS-CoV-2 IgG was conducted August 10–September 11. First coronavirus disease case in South Sudan was identified on April 2 and confirmed on April 4, 2020 (23). SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 1. Number of weekly SARS-CoV-2 tests and infections reported in Juba, South Sudan, May 3–October 30, 2020. The survey of seroprevalence of SARS-CoV-2 IgG was conducted August 10–September 11. First coronavirus disease case in South Sudan was identified on April 2 and confirmed on April 4, 2020 (23). SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Download

Main Article

References
  1. World Health Organization. Weekly epidemiological update: 16 March 2021 [cited 2021 Mar 18]. https://www.who.int/publications/m/item/weekly-epidemiological-update---16-march-2021
  2. Rice  BL, Annapragada  A, Baker  RE, Bruijning  M, Dotse-Gborgbortsi  W, Mensah  K, et al. Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. Nat Med. 2021;27:447–53. DOIPubMedGoogle Scholar
  3. Mbow  M, Lell  B, Jochems  SP, Cisse  B, Mboup  S, Dewals  BG, et al. COVID-19 in Africa: Dampening the storm? Science. 2020;369:624–6. DOIPubMedGoogle Scholar
  4. Chitungo  I, Dzobo  M, Hlongwa  M, Dzinamarira  T. COVID-19: unpacking the low number of cases in Africa. Public Health in Practice. 2020;1:100038. DOIGoogle Scholar
  5. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection [cited 2021 Feb 11]. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Seroepidemiology-2020.2
  6. Chen  X, Chen  Z, Azman  AS, Deng  X, Sun  R, Zhao  Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health. 2021;9:e598–609; Epub ahead of print. DOIPubMedGoogle Scholar
  7. Uyoga  S, Adetifa  IMO, Karanja  HK, Nyagwange  J, Tuju  J, Wanjiku  P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021;371:79–82. DOIPubMedGoogle Scholar
  8. Olayanju  O, Bamidele  O, Edem  F, Eseile  B, Amoo  A, Nwaokenye  J, et al. SARS-CoV-2 seropositivity in asymptomatic frontline health workers in Ibadan, Nigeria. Am J Trop Med Hyg. 2021;104:91–4. DOIPubMedGoogle Scholar
  9. Halatoko  WA, Konu  YR, Gbeasor-Komlanvi  FA, Sadio  AJ, Tchankoni  MK, Komlanvi  KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. PLoS One. 2020;15:e0242124. DOIPubMedGoogle Scholar
  10. Asuquo  MI, Effa  E, Otu  A, Ita  O, Udoh  U, Umoh  V, et al. Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients. Eur J Immunol. 2020;50:2025–40.
  11. Yadouleton  A, Sander  A-L, Moreira-Soto  A, Tchibozo  C, Hounkanrin  G, Badou  Y, et al. Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin. Emerg Infect Dis. 2021;27:233–7. DOIPubMedGoogle Scholar
  12. Chibwana  MG, Jere  KC, Kamng’ona  R, Mandolo  J, Katunga-Phiri  V, Tembo  D, et al. High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. medRxiv. 2020;5:199. DOIPubMedGoogle Scholar
  13. Nkuba Ndaye  A, Hoxha  A, Madinga  J, Mariën  J, Peeters  M, Leendertz  FH, et al. Challenges in interpreting SARS-CoV-2 serological results in African countries. Lancet Glob Health. 2021;9:e588–9. DOIPubMedGoogle Scholar
  14. Hsiao  M, Davies  M-A, Kalk  E, Hardie  D, Naidoo  M, Centner  C, et al. SARS-CoV-2 seroprevalence in the Cape Town metropolitan sub-districts after the peak of infections. COVID-19 Special Public Health Surveillance Bulletin. 2020;18(Suppl 5):1–9. Johannesburg (South Africa): National Institute for Communicable Diseases; 2021 [cited 2021 Mar 2]. https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf
  15. Milleliri  JM, Coulibaly  D, Nyobe  B, Rey  J-L, Lamontagne  F, Hocqueloux  L, et al. SARS-CoV-2 infection in Ivory Coast: a serosurveillance survey among gold mine workers. Am J Trop Med Hyg. 2021;tpmd210081; [Epub ahead of print].PubMedGoogle Scholar
  16. Mulenga  LB, Hines  JZ, Fwoloshi  S, Chirwa  L, Siwingwa  M, Yingst  S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Health. 2021;S2214-109X(21)00053-X; [Epub ahead of print].PubMedGoogle Scholar
  17. World Health Organization. South Sudan. South Sudan confirms first case of COVID-19 [cited 2021 Feb 23]. https://www.afro.who.int/news/south-sudan-confirms-first-case-covid-19
  18. Integrated Food Security Phase Classification. South Sudan: IPC results October 2020–July 2021 [cited 2021 Mar 4]. http://www.ipcinfo.org/ipcinfo-website/alerts-archive/issue-31
  19. International Organization for Migration Data Tracking Matrix. South Sudan—mobility tracking round 9 initial findings [cited 2021 Mar 4]. https://displacement.iom.int/reports/south-sudan-%E2%80%94-mobility-tracking-round-9-initial-findings
  20. International Organization for Migration, World Food Programme. Urban multi-sector needs, vulnerabilities and COVID-19 impact survey (FSNMS+): Juba Town [cited 2021 Mar 4]. https://migration.iom.int/reports/south-sudan-%E2%80%94-urban-multi-sector-needs-vulnerabilities-and-covid-19-impact-survey-fsnms-%E2%80%94
  21. Iyer  AS, Jones  FK, Nodoushani  A, Kelly  M, Becker  M, Slater  D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5:eabe0367. DOIPubMedGoogle Scholar
  22. Slater  DM. Preparation of elutions from dried blood spots for ELISAs [cited 2021 Mar 2]. https://www.protocols.io/view/preparation-of-elutions-from-dried-blood-spots-for-bsrnnd5e
  23. Iyer  AS, Azman  AS, Bouhenia  M, Deng  LO, Anderson  CP, Graves  M, et al. Dried blood spots for measuring Vibrio cholerae-specific immune responses. PLoS Negl Trop Dis. 2018;12:e0006196. DOIPubMedGoogle Scholar
  24. Huang  C, Wang  Y, Li  X, Ren  L, Zhao  J, Hu  Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. DOIPubMedGoogle Scholar
  25. Xu  Z, Shi  L, Wang  Y, Zhang  J, Huang  L, Zhang  C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2. DOIPubMedGoogle Scholar
  26. Republic of South Sudan Ministry of Health. Malaria indicator survey 2017: final report. 2019 [cited 2021 Feb 22]. https://www.malariasurveys.org/documents/SSMIS%202017%20final%20report%202019%2005%2020_signed%20(1).pdf
  27. Stringhini  S, Wisniak  A, Piumatti  G, Azman  AS, Lauer  SA, Baysson  H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313–9. DOIPubMedGoogle Scholar
  28. Carpenter  B, Gelman  A, Hoffman  MD, Lee  D, Goodrich  B, Betancourt  M, et al. Stan: a probabilistic programming language. J Stat Softw. 2017;76:1–32. DOIGoogle Scholar
  29. United Nations Office for the Coordination of Humanitarian Affairs, Integrated Food Security Phase Classification Technical Working Group, South Sudan National Bureau of Standards. South Sudan total population by county. 2020 [cited 2021 Mar 2]. https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/documents/files/ss_total_population_by_county_map_a4_20201116.pdf
  30. Tso  FY, Lidenge  SJ, Peña  PB, Clegg  AA, Ngowi  JR, Mwaiselage  J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577–83. DOIPubMedGoogle Scholar
  31. Emmerich  P, Murawski  C, Ehmen  C, von Possel  R, Pekarek  N, Oestereich  L, et al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop Med Int Health. 2021;•••:tmi.13569; Epub ahead of print. DOIPubMedGoogle Scholar
  32. World Health Organization. South Sudan. South Sudan launches a nationwide campaign to protect 2.5 million children against measles [cited 2021 Mar 2]. https://www.afro.who.int/news/south-sudan-launches-nationwide-campaign-protect-25-million-children-against-measles
  33. Takahashi  S, Greenhouse  B, Rodríguez-Barraquer  I. Are seroprevalence estimates for severe acute respiratory syndrome coronavirus 2 biased? J Infect Dis. 2020;222:1772–5. DOIPubMedGoogle Scholar
  34. Kutsuna  S, Asai  Y, Matsunaga  A. Loss of anti–SARS-CoV-2 antibodies in mild COVID-19. N Engl J Med. 2020;383:1695–6.PubMedGoogle Scholar
  35. Shirin  T, Bhuiyan  TR, Charles  RC, Amin  S, Bhuiyan  I, Kawser  Z, et al. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. Int J Infect Dis. 2020;101:220–5. DOIPubMedGoogle Scholar
  36. Choe  PG, Kim  K-H, Kang  CK, Suh  HJ, Kang  E, Lee  SY, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis. 2021;27:928–31. DOIPubMedGoogle Scholar
  37. Cervia  C, Nilsson  J, Zurbuchen  Y, Valaperti  A, Schreiner  J, Wolfensberger  A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147:545–557.e9. DOIPubMedGoogle Scholar
  38. Long  Q-X, Tang  X-J, Shi  Q-L, Li  Q, Deng  H-J, Yuan  J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–4. DOIPubMedGoogle Scholar
  39. Lynch  KL, Whitman  JD, Lacanienta  NP, Beckerdite  EW, Kastner  SA, Shy  BR, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2020;72:301–8. DOIPubMedGoogle Scholar
  40. Mwananyanda  L, Gill  CJ, MacLeod  W, Kwenda  G, Pieciak  R, Mupila  Z, et al. Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. BMJ. 2021;372:n334. DOIPubMedGoogle Scholar
  41. Oved  K, Olmer  L, Shemer-Avni  Y, Wolf  T, Supino-Rosin  L, Prajgrod  G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020;29:100651. DOIPubMedGoogle Scholar
  42. International Organization for Migration Data Tracking Matrix. Biometric registration. 2021 [cited 2021 Mar 4]. https://displacement.iom.int/component/biometric-registration

Main Article

1A portion of this research was presented at the United States–Japan Cooperative Medical Sciences Program—Virtual Workshop on COVID-19, February 24–26, 2021.

2These authors contributed equally to this article.

3These authors contributed equally to this article.

Page created: March 25, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external